196.07 +0.16 (0.08%)
Pre-Market: 8:55AM EDT
|Bid||195.91 x 800|
|Ask||197.00 x 1100|
|Day's Range||193.38 - 196.75|
|52 Week Range||163.31 - 201.23|
|PE Ratio (TTM)||64.19|
|Earnings Date||Jul 26, 2018|
|Forward Dividend & Yield||5.28 (2.72%)|
|1y Target Est||195.80|
"Halftime Report" trader Pete Najarian and Mad Money's Jim Cramer discuss unusual options activity in Amgen and the XOP energy ETF.
FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $140 million.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 12) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Arbutus Biopharma ...
THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY increases bone formation and reduces bone resorption simultaneously to increase bone mineral density (BMD) and reduce the risk of fracture. "A fracture due to osteoporosis can be a life-altering event, and EVENITY has the potential to reduce fracture risk in patients at high risk due to a prior fracture," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.
As the economy reaches the later stages of its cycle and profit growth slows, investors should take a look at Goldman Sachs’ basket of more than 30 Russell 1000 stocks with high gross profit margins that have proven stable over time. Seven of those stocks, which have been recent outperformers, include Verisign Inc. ( VRSN), Amgen Inc. ( AMGN), Cadence Design Systems Inc. ( CDNS), Adobe Systems Inc. ( ADBE), IDEXX Laboratories Inc. ( IDXX), Liberty Media Corp. ( LSXMA) and O’Reilly Automotive Inc. ( ORLY).
This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $820 million.
According to Incyte Corporation (INCY), the firm is a “Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.”
Shares of Amgen also moved north as Wall Street's celebration of Biogen's news pushed many biotech stocks higher. Biogen Inc. shares were jumping on Friday, closing the day up almost 20% on high volume compared to usual. The company along with Eisai Co. Ltd. of Japan had announced positive results from an Alzheimer's study.
Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.
The NASDAQ Biotechnology Index rose about 3% in midday trading Friday to 3,636.45, the highest level since February. underperforming the overall NASDAQ Index in the past year, investors might be recognizing the hidden value of the firms' drug research and development, says Steve Chesney, an analyst for Atlantic Equities in London who covers large cap biotech firms worth more than $60 billion. Celgene, a biotechnology company which develops anti-inflammatory drugs for cancer and other diseases rose around 2% to $82.09 in early afternoon trading.
In this daily bar chart of AMGN, below, we can see a number of bullish developments. The daily On-Balance-Volume (OBV) line shows an uptrend from November signaling more aggressive buying for months. In this weekly bar chart of AMGN, below, we can see an uptrend from late 2016.
Amgen (AMGN) discovers, develops, and delivers drugs for various therapeutic areas, including cardiovascular disease, neuroscience, and oncology. The chart below shows Amgen’s revenue and EPS since Q1 2017, and analysts’ estimate for Q2 2018.
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.